{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-006255","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2022-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.728416+00:00","generated_at":"2026-06-26T22:59:29.379745+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Champions Oncology Q3 revenue record $13.2M, up 22% YoY; adj. EBITDA $1.5M","bullets":["Revenue of $13.2M for quarter ended Jan 31, 2022, a 22% increase from $10.8M in prior year.","Adjusted EBITDA was $1.5M; net income from operations of $830K (incl. $310K stock comp).","Gross margin for Q3 was 51.4% vs 57.2% a year ago; nine-month gross margin improved to 51.9% from 48.8%.","Cash position $8.7M with no debt; signed co-development partnerships with Fannin Innovation Studio and Gigamune.","Company reaffirms FY2022 revenue growth guidance of 15%-20%."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-006255","json":"https://secwatch.observer/filing/0001628280-22-006255.json","markdown":"https://secwatch.observer/filing/0001628280-22-006255.md","text":"https://secwatch.observer/filing/0001628280-22-006255.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828022006255/0001628280-22-006255-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828022006255/csbr-20220315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:59:29.379745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}